Literature DB >> 16054806

Genome profiling of melanocytic tumors using multiplex ligation-dependent probe amplification (MLPA): Its usefulness as an adjunctive diagnostic tool for melanocytic tumors.

Minoru Takata1, Takefumi Suzuki, Shinichi Ansai, Tetsunori Kimura, Fumiaki Shirasaki, Naohito Hatta, Toshiaki Saida.   

Abstract

BACKGROUND: The histopathology of melanocytic tumors sometimes presents diagnostic problems. Applicable parameters other than routine pathology are needed.
OBJECTIVE: We assessed the feasibility of multiplex ligation-dependent probe amplification (MLPA), a novel PCR-based genome profiling method, in the classification of melanocytic tumors.
METHOD: We extracted DNA from paraffin-embedded tissue sections of 24 primary melanomas, 14 Spitz nevi and 17 common melanocytic nevi. We analyzed the copy number gains or losses of a total of 76 genes spanning almost all chromosome arms using commercially available MLPA kits.
RESULTS: Although four melanocytic nevi and three Spitz nevi did not yield sufficient DNA for reliable analysis due to small tumor size, the MLPA analysis was feasible and applicable to the remaining 88% of samples. We found multiple genetic aberrations in primary melanomas. The total number of aberrations in each tumor ranged from 1 to 32 (average, 12.04). All but two melanomas showed aberrations at more than three genetic loci. Seventeen (70.8%) of the 24 melanomas showed a copy number loss of either the CDKN2A or CDKN2B gene on chromosome 9p21. All the Spitz nevi and 7 (50%) of 14 common melanocytic nevi had copy number changes at one or two gene loci (average, 1.04). The receiver operator characteristic curve analysis showed that the threshold value of copy number aberrations corresponding to 98% specificity for melanoma was 2.42 and the sensitivity using this threshold value was 92.5%.
CONCLUSIONS: MLPA could be used as an adjunctive diagnostic tool for melanocytic tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054806     DOI: 10.1016/j.jdermsci.2005.06.009

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  6 in total

1.  Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

Authors:  Elisabetta Vergani; Viviana Vallacchi; Simona Frigerio; Paola Deho; Piera Mondellini; Paola Perego; Giuliana Cassinelli; Cinzia Lanzi; Maria Adele Testi; Licia Rivoltini; Italia Bongarzone; Monica Rodolfo
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience.

Authors:  Eiman A Al Zaabi; Louis A Fernandez; Irene A Sadek; D Christie Riddell; Wenda L Greer
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

3.  Genetic copy number alterations and IL-13 expression differences in papillary thyroid cancers and benign nodules.

Authors:  ZeFei Zhao; Qing Wei; Yongju Zhao; Fukang Sun; Xiaolong Jin; Bin Cui; Guang Ning
Journal:  Endocrine       Date:  2009-06-09       Impact factor: 3.633

4.  Prenatal diagnosis of PLP1 duplication by single nucleotide polymorphism array in a family with Pelizaeus-Merzbacher disease.

Authors:  Huili Xue; Aili Yu; Xuemei Chen; Na Lin; Min Lin; Hailong Huang; Liangpu Xu
Journal:  Aging (Albany NY)       Date:  2021-01-11       Impact factor: 5.682

5.  Expanding spectrum of "spitzoid" lesions: a small series of 4 cases with MAP2K1 mutations.

Authors:  K G P Kerckhoffs; T Aallali; C A Ambarus; V Sigurdsson; A M L Jansen; W A M Blokx
Journal:  Virchows Arch       Date:  2020-10-11       Impact factor: 4.064

6.  Identification of proteolipid protein 1 gene duplication by multiplex ligation-dependent probe amplification: first report of genetically confirmed family of Pelizaeus-Merzbacher disease in Korea.

Authors:  Sei Joo Kim; Joon Shik Yoon; Hye Jin Baek; Sang Il Suh; Sook Young Bae; Hyun-Jung Cho; Chang-Seok Ki
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.